Xiaoxi Zhou

2.5k total citations
53 papers, 1.0k citations indexed

About

Xiaoxi Zhou is a scholar working on Oncology, Immunology and Pathology and Forensic Medicine. According to data from OpenAlex, Xiaoxi Zhou has authored 53 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Oncology, 14 papers in Immunology and 11 papers in Pathology and Forensic Medicine. Recurrent topics in Xiaoxi Zhou's work include CAR-T cell therapy research (23 papers), Lymphoma Diagnosis and Treatment (11 papers) and Virus-based gene therapy research (8 papers). Xiaoxi Zhou is often cited by papers focused on CAR-T cell therapy research (23 papers), Lymphoma Diagnosis and Treatment (11 papers) and Virus-based gene therapy research (8 papers). Xiaoxi Zhou collaborates with scholars based in China, United States and Russia. Xiaoxi Zhou's co-authors include Jianfeng Zhou, Qiangying Yi, Yao Wu, Liting Chen, Ke Kang, Min Xiao, Xia Mao, Chunrui Li, Fang Lan and Jue Wang and has published in prestigious journals such as The Journal of Experimental Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Xiaoxi Zhou

52 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Xiaoxi Zhou China 20 579 342 251 211 149 53 1.0k
Jianhong Chu China 18 723 1.2× 405 1.2× 185 0.7× 830 3.9× 129 0.9× 26 1.4k
Philipp Mayer‐Kuckuk United States 18 340 0.6× 648 1.9× 189 0.8× 96 0.5× 141 0.9× 38 1.4k
Mahboubeh Yazdanifar United States 17 624 1.1× 307 0.9× 168 0.7× 448 2.1× 30 0.2× 29 988
ZeNan Chang United States 12 407 0.7× 297 0.9× 161 0.6× 177 0.8× 61 0.4× 15 729
Hongliang Fang China 9 244 0.4× 191 0.6× 185 0.7× 219 1.0× 46 0.3× 10 600
Constantina Christodoulou United States 12 211 0.4× 894 2.6× 126 0.5× 156 0.7× 184 1.2× 15 1.8k
Si Li China 16 707 1.2× 362 1.1× 201 0.8× 265 1.3× 16 0.1× 51 1.1k
Bindu Varghese United States 15 675 1.2× 419 1.2× 142 0.6× 1.4k 6.4× 91 0.6× 25 2.1k
Wenhao Zhang China 16 391 0.7× 288 0.8× 54 0.2× 298 1.4× 139 0.9× 88 898
Jorrit De Waele Belgium 19 594 1.0× 470 1.4× 163 0.6× 525 2.5× 19 0.1× 36 1.4k

Countries citing papers authored by Xiaoxi Zhou

Since Specialization
Citations

This map shows the geographic impact of Xiaoxi Zhou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaoxi Zhou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaoxi Zhou more than expected).

Fields of papers citing papers by Xiaoxi Zhou

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiaoxi Zhou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaoxi Zhou. The network helps show where Xiaoxi Zhou may publish in the future.

Co-authorship network of co-authors of Xiaoxi Zhou

This figure shows the co-authorship network connecting the top 25 collaborators of Xiaoxi Zhou. A scholar is included among the top collaborators of Xiaoxi Zhou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiaoxi Zhou. Xiaoxi Zhou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lin, Haolong, et al.. (2024). Hepatitis B virus reactivation associated with CAR T-cell therapy. 3(1). 2 indexed citations
2.
Zhang, Shiyuan, et al.. (2024). A single‐centre, real‐world study of BTK inhibitors for the initial treatment of MYD88mut/CD79Bmut diffuse large B‐cell lymphoma. Cancer Medicine. 13(4). e7005–e7005. 6 indexed citations
3.
Ba, Hongping, Zunyue Zhang, Peng Zhang, et al.. (2023). Antitumor effect of CAR-T cells targeting transmembrane tumor necrosis factor alpha combined with PD-1 mAb on breast cancers. Journal for ImmunoTherapy of Cancer. 11(1). e003837–e003837. 17 indexed citations
4.
Jin, Jin, Tianjiao Liu, Jiali Cheng, et al.. (2023). MIP3α as an early prognostic predictor for patients with B-cell malignancies receiving CD19/CD22-redirected CAR-T cell cocktail therapy. Cancer Immunology Immunotherapy. 72(7). 2245–2256. 3 indexed citations
5.
Mu, Wei, Meilan Zhang, Guang Hu, et al.. (2023). Case report: Differential diagnosis of highly amplified anti-CD5 CAR T cells and relapsed lymphoma cells in a patient with refractory ALK positive anaplastic large cell lymphoma. Frontiers in Immunology. 14. 1280007–1280007. 2 indexed citations
6.
7.
Cheng, Jiali, Jue Wang, Xia Mao, et al.. (2023). Phase 1 Dose Escalation Study of the Anti-CD7 CAR-T Therapy in Relapsed/Refractory T-Cell Acute Leukemia and Lymphoblastic Lymphoma. Blood. 142(Supplement 1). 6863–6863. 2 indexed citations
8.
Zhou, Lanlan, et al.. (2022). Clinical characteristics and prognosis of 16 relapsed/refractory B-cell malignancy patients with CAR T-cell-related hyperferritinaemia. Frontiers in Oncology. 12. 912689–912689. 1 indexed citations
9.
Ba, Hongping, Rui Jiang, Meng Zhang, et al.. (2021). Suppression of Transmembrane Tumor Necrosis Factor Alpha Processing by a Specific Antibody Protects Against Colitis-Associated Cancer. Frontiers in Immunology. 12. 687874–687874. 6 indexed citations
10.
11.
Zhou, Xiaoxi, Gaoxiang Wang, Liting Chen, et al.. (2020). Clinical characteristics of hematological patients concomitant with COVID‐19. Cancer Science. 111(9). 3379–3385. 12 indexed citations
12.
Zhao, Lei, Yuanyuan Zhang, Yi Xiao, et al.. (2020). CAR T-Cell Therapy Is Effective but Not Long-Lasting in B-Cell Lymphoma of the Brain. Frontiers in Oncology. 10. 1306–1306. 32 indexed citations
13.
Lou, Yaoyao, Caixia Chen, Xiaolu Long, et al.. (2020). Detection and Quantification of Chimeric Antigen Receptor Transgene Copy Number by Droplet Digital PCR versus Real-Time PCR. Journal of Molecular Diagnostics. 22(5). 699–707. 39 indexed citations
14.
Zhang, Yuanyuan, et al.. (2019). A good response of refractory mantel cell lymphoma to haploidentical CAR T cell therapy after failure of autologous CAR T cell therapy. Journal for ImmunoTherapy of Cancer. 7(1). 51–51. 15 indexed citations
15.
Zhang, Yixian, Yangwei Wang, Manyu Luo, et al.. (2019). Elabela protects against podocyte injury in mice with streptozocin-induced diabetes by associating with the PI3K/Akt/mTOR pathway. Peptides. 114. 29–37. 47 indexed citations
16.
Huang, Liang, Na Wang, Yang Cao, et al.. (2018). CAR22/19 Cocktail Therapy for Patients with Refractory/Relapsed B-Cell Malignancies. Blood. 132(Supplement 1). 1408–1408. 20 indexed citations
17.
Patel, Seema R., David R. Gibb, Kathryn R. Girard‐Pierce, et al.. (2018). Marginal Zone B Cells Induce Alloantibody Formation Following RBC Transfusion. Frontiers in Immunology. 9. 2516–2516. 34 indexed citations
18.
Zhan, Xiaohui, Qiangying Yi, Shuang Cai, et al.. (2017). Polymer-entanglement-driven coassembly of hybrid superparamagnetic nanoparticles: Tunable structures and flexible functionalization. Journal of Colloid and Interface Science. 508. 263–273. 5 indexed citations
19.
20.
Wu, Ying, Min Xiao, Li Zhu, et al.. (2011). [CD96 expression on bone marrow mononuclear cells in 91 patients with acute leukemia].. PubMed. 19(3). 585–8. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jianhong Chu Breakdown of academic impact, for papers by Philipp Mayer‐Kuckuk Breakdown of academic impact, for papers by Mahboubeh Yazdanifar Breakdown of academic impact, for papers by ZeNan Chang Breakdown of academic impact, for papers by Hongliang Fang Breakdown of academic impact, for papers by Constantina Christodoulou Breakdown of academic impact, for papers by Si Li Breakdown of academic impact, for papers by Bindu Varghese Breakdown of academic impact, for papers by Wenhao Zhang Breakdown of academic impact, for papers by Jorrit De Waele
Rankless by CCL
2026